STAT20h
With RFK Jr. looming as health secretary, pharma execs try to project stability
LONDON — Robert F. Kennedy Jr. has been a vocal critic of the pharma industry. He’s said it’s corrupted U.S. health agencies ...
STAT5h
Pharmalittle: We’re reading about a key Merck drug trial, cheap Wegovy in China, and more
Merck reported that a new formulation of Keytruda appears to deliver similar blood levels of the drug when given as a shot as ...
STAT5h
A win for Apellis, a setback for Astellas
The FDA rejected an application from Astellas seeking to change the prescribing label for its eye drug Izervay to allow less ...
STAT7h
Former NCI chief and serial biotech entrepreneur raise $70 million to start companies that fail fast
Jupiter has raised $70 million from investors including Mission BioCapital and the Mayo Clinic to start small biotechs that ...
STAT7h
Pharma still ‘falling short’ in providing access to low- and middle-income countries, analysis finds
More pharma companies are tailoring their business models to focus on low-income countries. But a new analysis finds overall ...
STAT6h
Why the crowded market for ambient AI medical scribes might be ripe for consolidation
Even as more health systems adopt ambient scribes, the technology providers might find it harder to differentiate themselves, ...
STAT10h
The many legal fronts of RFK Jr.’s fight against vaccines
Robert F. Kennedy Jr.'s nonprofit, Children’s Health Defense, is involved in vaccine lawsuits against agencies he could wind ...
STAT10h
In first meeting of FDA’s digital health advisory committee, generative AI is up for debate
The FDA's digital health advisory committee is expected to weigh in on how generative AI should be regulated by the agency.
STAT10h
The FDA’s risky action on compounding weight loss drugs
The FDA’s decision to allow the compounding of GLP-1 weight loss drugs could undermine its public health obligations, writes ...
STAT11h
Two drugs look promising for lipoprotein(a), a common genetic risk factor for heart disease
At AHA, Phase 2 results from Eli Lilly and Silence Therapeutics are seen as signs of a "major new path" of cardiovascular ...
STAT8h
Merck says study of under-the-skin version of Keytruda, a bid to extend the drug’s sales, succeeded
Merck's new formulation could help secure a larger share of Keytruda's sales after the cancer drug's U.S. patent expires in ...
STAT23h
H5N1 bird flu virus in Canadian teenager displays mutations demonstrating virus’ risk
The H5N1 virus that infected a Canadian teen appears not to have spread, but it shows signs of mutation that makes flu ...